Advanced search
Publication Cover
Cancer Investigation Volume 39, 2021 - Issue 6-7
Submit an article Journal homepage
1,000
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience

Aykut Bahçecia Department of Medical Oncology, Dr. Ersin Arslan Education and Research Hospital, Gaziantep, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7921-5204
ORCID Icon,
Semra Paydaşb Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, TurkeyORCID Iconhttps://orcid.org/0000-0003-4642-3693
ORCID Icon,
Naziye Akc Department of Medical Oncology, Institute of Oncology, İstanbul University, İstanbul, TurkeyORCID Iconhttps://orcid.org/0000-0001-5790-7066
ORCID Icon,
Ferhat Ferhatoğluc Department of Medical Oncology, Institute of Oncology, İstanbul University, İstanbul, TurkeyORCID Iconhttps://orcid.org/0000-0002-7651-6789
ORCID Icon,
Pınar Mualla Saipc Department of Medical Oncology, Institute of Oncology, İstanbul University, İstanbul, TurkeyORCID Iconhttps://orcid.org/0000-0001-6871-8519
ORCID Icon,
Gülşah Seydaoğlud Department of Biostatistics, University of Cukurova, Adana, TurkeyORCID Iconhttps://orcid.org/0000-0002-0899-894X
ORCID Icon,
Mehmet Bilicie Department of Medical Oncology, Faculty of Medicine, Atatürk University, Erzurum, Turkey
,
Melih Şimşeke Department of Medical Oncology, Faculty of Medicine, Atatürk University, Erzurum, Turkey
,
Salim Başol Tekine Department of Medical Oncology, Faculty of Medicine, Atatürk University, Erzurum, Turkey
,
Züleyha Çalikuşuf Department of Medical Oncology, Acibadem Adana Hospital, Acibadem MAA University, Adana, TurkeyORCID Iconhttps://orcid.org/0000-0003-0875-1485
ORCID Icon,
Sinan Yavuzf Department of Medical Oncology, Acibadem Adana Hospital, Acibadem MAA University, Adana, TurkeyORCID Iconhttps://orcid.org/0000-0002-1479-6439
ORCID Icon,
Ahmet Bilgehan Şahing Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, TurkeyORCID Iconhttps://orcid.org/0000-0002-7846-0870
ORCID Icon,
Erdem Çubukçug Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, TurkeyORCID Iconhttps://orcid.org/0000-0002-0070-0889
ORCID Icon,
Türkkan Evrenselg Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, TurkeyORCID Iconhttps://orcid.org/0000-0002-9732-5340
ORCID Icon,
Serkan Değirmencioğluh Department of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli, TurkeyORCID Iconhttps://orcid.org/0000-0002-1213-2778
ORCID Icon,
Atike Gökçen Demirayh Department of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli, TurkeyORCID Iconhttps://orcid.org/0000-0003-4397-5468
ORCID Icon,
Perran Fulden Yumuki Division of Medical Oncology, School of Medicine, Marmara University, Istanbul, TurkeyORCID Iconhttps://orcid.org/0000-0001-8650-299X
ORCID Icon,
Özkan Alani Division of Medical Oncology, School of Medicine, Marmara University, Istanbul, TurkeyORCID Iconhttps://orcid.org/0000-0002-6635-2012
ORCID Icon,
Duygu İlke Çikmanj Department of Medical Oncology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
,
Fuat Hulusi Demirellij Department of Medical Oncology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
,
Osman Köstekk Department of Medical Oncology, Trakya University, Edirne, TurkeyORCID Iconhttps://orcid.org/0000-0002-1901-5603
ORCID Icon,
Ali Gökyerk Department of Medical Oncology, Trakya University, Edirne, TurkeyORCID Iconhttps://orcid.org/0000-0002-1653-6155
ORCID Icon,
Mutlu Doğanl Department of Medical Oncology, Numune Education and Research Hospital, University of Health Sciences, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0001-9359-3770
ORCID Icon,
Öznur Ball Department of Medical Oncology, Numune Education and Research Hospital, University of Health Sciences, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0002-6901-2646
ORCID Icon,
Burcu Çakarm Department of Medical Oncology, Ege University, Izmir, TurkeyORCID Iconhttps://orcid.org/0000-0003-3790-791X
ORCID Icon,
Erhan Gökmenm Department of Medical Oncology, Ege University, Izmir, TurkeyORCID Iconhttps://orcid.org/0000-0003-4596-2986
ORCID Icon,
Deniz Yamaçn Department of Medical Oncology, Ankara Güven Hospital, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0002-9385-3875
ORCID Icon,
Taner Korkmazo Acıbadem MAA University School of Medicine, Medical Oncology Division, Acibadem Research Institiute of Senology (Maslak Hospital)ORCID Iconhttps://orcid.org/0000-0003-4292-0545
ORCID Icon,
Altay Aliyevp Department of Medical Oncology, Faculty of Medicine, Bezmialem University, Istanbul, TurkeyORCID Iconhttps://orcid.org/0000-0002-2024-7751
ORCID Icon,
Özge Keskinq Department of Medical Oncology, Selçuk University, Konya, TurkeyORCID Iconhttps://orcid.org/0000-0002-8062-0116
ORCID Icon,
Semiha Urvayr Department of Medical Oncology, Acibadem Kayseri Hospital, Acibadem MAA University, Kayseri, TurkeyORCID Iconhttps://orcid.org/0000-0002-0181-3842
ORCID Icon,
Mahmut Büyükşimşekb Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey
,
Cemile Karadenizs Department of Medical Oncology, Hatay Antakya State Hospital, Hatay, Turkey
,
Birol Yildizt Department of Medical Oncology, Gulhane Education and Research Hospital, University of Health Sciences, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0001-8920-6467
ORCID Icon,
Havva Yeşil Çinkiru Department of Medical Oncology, Gaziantep University, Gaziantep, TurkeyORCID Iconhttps://orcid.org/0000-0002-7870-8741
ORCID Icon,
Hacer Demirv Department of Medical Oncology, Kayseri Education and Research Hospital
,
İsmail Beypinarw Department of Medical Oncology, Faculty of Medicine, Afyon Kocatepe University, Afyonkarahisar, TurkeyORCID Iconhttps://orcid.org/0000-0002-0853-4096
ORCID Icon,
Cengiz Karaçinx Department of Medical Oncology, Ankara Diskapi Education and Research Hospital, University of Health Sciences, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0002-7310-9328
ORCID Icon,
Kadir Esery Department of Medical Oncology, Mersin University, Mersin, TurkeyORCID Iconhttps://orcid.org/0000-0001-8666-6177
ORCID Icon,
Meltem Baykaraz Department of Medical Oncology, Faculty of Medicine, Sakarya University, Sakarya, TurkeyORCID Iconhttps://orcid.org/0000-0003-3291-8134
ORCID Icon,
Saadettin Kiliçkapaa Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0003-1637-7390
ORCID Icon,
Kerem Okuturbb Department of Medical Oncology, Istanbul Memorial Bahcelievler Hospital, Istanbul, TurkeyORCID Iconhttps://orcid.org/0000-0002-8079-7739
ORCID Icon,
Gülcan Bulutcc Department of Medical Oncology, Antakya Defne Hospital, Hatay, TurkeyORCID Iconhttps://orcid.org/0000-0001-7382-0972
ORCID Icon,
Ali Alkandd Department of Medical Oncology, Mugla Sıtkı Kocman University, Mugla, TurkeyORCID Iconhttps://orcid.org/0000-0002-8253-5046
ORCID Icon,
Erkan Arpaciee Department of Medical Oncology, Kocaeli Gebze Medicalpark Hospital, Kocaeli, Turkey
,
Kezban Nur Pilanciff Department of Medical Oncology, Istanbul Aydın University, Istanbul, Turkey
,
Atakan Demirn Department of Medical Oncology, Ankara Güven Hospital, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0002-1940-4086
ORCID Icon,
Deniz Işika Department of Medical Oncology, Dr. Ersin Arslan Education and Research Hospital, Gaziantep, Turkey
&
Nilgün Yildirima Department of Medical Oncology, Dr. Ersin Arslan Education and Research Hospital, Gaziantep, Turkey
 show all
Pages 473-481 | Received 12 Sep 2020, Accepted 16 May 2021, Published online: 07 Jun 2021
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Aim

The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment.

Method

Retrospective analysis of T-DM1 results of human epidermal growth factor receptor 2 (Her2) positive 414 cases with mBC from 31 centers in Turkey.

Findings

Except 2, all of the cases were female with a median age of 47. T-DM1 had been used as second-line therapy in 37.7% of the cases and the median number of T-DM1 cycles was 9. Progression-free survival (PFS) and overall survival (OS) times were different according to the line of treatment. The median OS was found as 43, 41, 46, 23 and 17 months for 1st, 2nd, 3rd, 4th and 5th line, respectively (p = 0.032) while the median PFS was found as 37, 12, 8, 8 and 8 months, respectively (p = 0.0001). Treatment was well tolerated by the patients. The most common grade 3–4 adverse effects were thrombocytopenia (2.7%) and increased serum gamma-glutamyl transferase (2%).

Discussion

The best of our knowledge this is the largest real-life experience about the safety and efficacy of T-DM1 use in cases with mBC after progression of Her2 targeted treatment. This study suggests and supports that T-DM1 is more effective in earlier lines of treatment and is a reliable option for mBC.

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Çukurova University Ethical Comittee: 13.4.2018; Number 76.

Human/animal rights statement

This article does not contain any studies with animals performed by any of the authors.

Informed consent

Given the retrospective nature of the study, written informed consent was not mandatory according to local regulations.

Declaration of interest

The authors declare no conflict of interest.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,193.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.